USSTOCK.TODAY
Regular Market
Log in Sign up

Revolution Medicines Receives FDA Approval for Pancreatic Cancer Treatment, Raising Royalty Pharma Revenue Expectations

The Motley Fool +1 · ·by G4L

RVMD Revolution Medicines Inc
$193.06 -3.54%
View chart & analysis →
RPRX +0.99%
  1. 1The FDA approved Darzasimel in August 2026.
  2. 2Revolution Medicines' Darzasimel is expected to reach peak sales of approximately $11 billion.
  3. 3Royalty Pharma's peak royalties for Darzasimel are expected to be approximately $340 million.

So what's the key point?

Revolution Medicines' pancreatic cancer treatment has received FDA approval. With sales of this drug expected to reach $11 billion, Royalty Pharma's revenue is also anticipated to grow.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Revolution Medicines beats revenue estimates with RASONQUE launch Earnings Whispers +3 · 6d agoRoyalty Pharma to Announce Third Quarter Results Before US Market Open on November 4 The Motley Fool +1 · Oct 29Revolution Medicines Receives Pancreatic Cancer Treatment Approval and Increases Stake The Motley Fool +1 · Oct 29
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news